• Agilent Technologies : Wells Fargo drops coverage on the stock.
  • Ameriprise Financial : Goldman Sachs upgrades to buy from neutral with a price target raised from USD 355 to USD 452.
  • Aptiv : Baird downgrades to neutral from outperform with a price target reduced from USD 105 to USD 96.
  • Avantor : Wells Fargo drops coverage on the stock.
  • Bio-Rad Laboratories : Wells Fargo drops coverage on the stock.
  • Blackstone : Goldman Sachs downgrades to neutral from buy with a price target raised from USD 115 to USD 128.
  • Citigroup : Wolfe Research upgrades to outperform from peerperform with a target price of USD 58.
  • Cme Group : Goldman Sachs downgrades to sell from neutral with a price target reduced from USD 217 to USD 195.
  • Danaher Corporation : Wells Fargo drops coverage on the stock.
  • Discover Financial Services : Piper Sandler & Co upgrades to overweight from neutral with a price target raised from USD 104 to USD 129.
  • Hologic : Wells Fargo drops coverage on the stock.
  • Huntington Bancshares : Evercore ISI upgrades to outperform from in-line with a price target raised from USD 10.50 to USD 15.
  • Icon : Wells Fargo drops coverage on the stock.
  • Iqvia Holdings : Wells Fargo drops coverage on the stock.
  • Kellanova : Edward Jones drops coverage on the stock.
  • Keurig Dr Pepper : Morgan Stanley downgrades to equal weight from overweight with a target price of USD 37.
  • Laboratory Corporation Of America Holdings : Wells Fargo drops coverage on the stock.
  • Mettler-Toledo International : Wells Fargo drops coverage on the stock.
  • Northern Trust Corporation : Wolfe Research downgrades to underperform from peerperform with a target price of USD 85.
  • Prudential Financial : JP Morgan downgrades to neutral from overweight with a target price reduced from USD 119 to USD 118.
  • Quest Diagnostics : Wells Fargo drops coverage on the stock.
  • Raymond James Financial : Goldman Sachs downgrades to neutral from buy with a price target reduced from USD 125 to USD 116.
  • Regions Financial Corporation : Evercore ISI downgrades to in-line from outperform with a price target raised from USD 16.50 to USD 21.
  • Revvity : Wells Fargo drops coverage on the stock.
  • Rocket Companies : Wells Fargo downgrades to equalweight from overweight with a price target raised from USD 13 to USD 14. Keefe Bruyette & Woods downgrades to underperform from market perform with a target price of USD 10.75.
  • Charles Schwab : Goldman Sachs downgrades to neutral from buy with a price target raised from USD 70 to USD 71.
  • State Street Corporation : Goldman Sachs upgrades to buy from neutral with a price target raised from USD 69 to USD 92.
  • The Sherwin-Williams Company : Baird downgrades to neutral from outperform with a price target raised from USD 270 to USD 300.
  • Thermo Fisher Scientific : Wells Fargo drops coverage on the stock.
  • Verizon Communications : KeyBanc Capital Markets upgrades to overweight from sector weight with a target price of USD 45.
  • Waters Corporation : Wells Fargo drops coverage on the stock.
  • Yum! Brands : Barclays upgrades to overweight from equalweight with a price target raised from USD 126 to USD 146.
  • Amazon.com : D.A. Davidson maintains its buy recommendation and raises the target price from USD 157 to USD 195.
  • American Express Company : Evercore ISI maintains its in-line recommendation and raises the target price from USD 155 to USD 200.
  • Atlassian Corporation : Canaccord Genuity maintains its buy recommendation and raises the target price from USD 195 to USD 240.
  • Broadcom : Baptista Research maintains its hold recommendation with a price target raised from USD 957.80 to USD 1198.
  • Capital One Financial Corporation : Evercore ISI maintains its outperform rating and raises the target price from USD 119 to USD 152.
  • Citizens Financial Group : Evercore ISI maintains its in-line recommendation and raises the target price from USD 25 to USD 35.
  • Dexcom : Wolfe Research maintains its outperform rating and raises the target price from USD 115 to USD 145.
  • Expedia Group : Wolfe Research maintains its underperform recommendation and raises the target price from USD 90 to USD 120.
  • Fifth Third Bancorp : Evercore ISI maintains its in-line recommendation and raises the target price from USD 26 to USD 38.
  • M&T Bank Corporation : Evercore ISI maintains its in-line recommendation and raises the target price from USD 121 to USD 146.
  • Pnc Financial Services Group : Evercore ISI maintains its outperform rating and raises the target price from USD 134 to USD 180.
  • Servicenow : Canaccord Genuity maintains its buy recommendation and raises the target price from USD 625 to USD 755.
  • Symbotic : Goldman Sachs maintains a neutral recommendation with a price target raised from USD 40 to USD 51.
  • Synchrony Financial : Evercore ISI maintains its outperform rating and raises the target price from USD 33 to USD 44.
  • Us Bancorp : Evercore ISI maintains its in-line recommendation and raises the target price from USD 34 to USD 46.
  • Wells Fargo & Company : Evercore ISI maintains its outperform rating and raises the target price from USD 47 to USD 58.
  • Astrazeneca : Jefferies downgrades to hold from buy with a target price reduced from GBX 12500 to GBX 11000.
  • Burberry Group : Stifel downgrades to hold from buy and reduces the target price from GBX 1950 to GBX 1550.
  • First Quantum Minerals : BNP Paribas Exane maintains its neutral recommendation with a price target reduced from 18 to CAD 11.60.
  • Gsk : Jefferies upgrades to buy from hold with a price target raised from GBX 1550 to GBX 1900. Jefferies upgrades to buy from hold with a price target raised from USD 38.50 to USD 48.
  • Howden Joinery Group : Investec downgrades to hold from buy with a target price raised from GBX 800 to GBX 845.
  • Intercontinental Hotels Group : Bernstein maintains its market perform recommendation and raises the target price from 5766 to GBX 6900.
  • Magna International : Goldman Sachs downgrades to neutral from buy with a target price of CAD 77. Goldman Sachs maintains a neutral recommendation with a price target reduced from USD 73 to USD 58.